NIP
KYNB

Nicholas Investment Partners’s Kyntra Bio KYNB Stock Holding History

Nicholas Investment Partners’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,821
Closed -$2.45M – 255
2017
Q3 		$2.45M Buy
+1,821
New +$1.92M 0.17% 196

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Nicholas Investment Partners's KYNB Position: Q4 2017 in Review

Nicholas Investment Partners sold out of Kyntra Bio (KYNB) in Q4 2017, closing a stake of 1,821 shares — an estimated $2.45M sold.

Nicholas Investment Partners first reported a position in KYNB in Q3 2017 and held it in 1 quarter. The position peaked at $2.45M in Q3 2017. 187 funds tracked by Wall St. Rank hold KYNB as of Q4 2017.

  • Nicholas Investment Partners reported no remaining Kyntra Bio position as of Q4 2017 after selling out during the quarter.
  • Nicholas Investment Partners sold 1,821 Kyntra Bio shares in Q4 2017, an estimated $2.45M.
  • Nicholas Investment Partners first reported a position in Kyntra Bio in Q3 2017 and held it in 1 quarter.
  • Nicholas Investment Partners's Kyntra Bio position peaked at $2.45M in Q3 2017.
  • 187 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2017.

Based on Nicholas Investment Partners's 13F filing for Q4 2017, filed 14 Feb 2018.